Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% Higher - Should You Buy?

Key Points

• Cytek Biosciences shares rose 8.5% to $4.5550 in Monday trading, although volume was 41% below the stock’s average session volume.
• Analyst sentiment remains mixed: three analysts rate the stock Buy, two Hold, and one Sell, resulting in a consensus “Hold” rating and a $5.56 average price target.
• The company reported quarterly revenue of $48.14 million, exceeding expectations, while its EPS loss of $0.09 matched forecasts. Cytek remains unprofitable, with a negative net margin of 38.98%, and institutional investors own 69.46% of its shares.

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report)'s share price was up 8.5% on Monday . The company traded as high as $4.52 and last traded at $4.5550. 601,077 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 1,023,583 shares. The stock had previously closed at $4.20.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Wednesday, June 24th. Morgan Stanley set a $5.00 target price on shares of Cytek Biosciences in a research report on Friday. Finally, Stephens cut their price target on shares of Cytek Biosciences from $5.50 to $4.75 and set an "overweight" rating on the stock in a report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cytek Biosciences currently has a consensus rating of "Hold" and a consensus target price of $5.56.

Cytek Biosciences Stock Performance

The stock has a market capitalization of $592.06 million, a price-to-earnings ratio of -7.33 and a beta of 1.17. The firm has a fifty day moving average of $4.32 and a 200-day moving average of $4.40.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). Cytek Biosciences had a negative return on equity of 12.40% and a negative net margin of 38.98%.The company had revenue of $48.14 million for the quarter, compared to analysts' expectations of $47.31 million. On average, analysts predict that Cytek Biosciences, Inc. will post -0.21 EPS for the current year.

Institutional Trading of Cytek Biosciences

Several large investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. lifted its position in shares of Cytek Biosciences by 99.6% during the fourth quarter. SBI Securities Co. Ltd. now owns 5,010 shares of the company's stock worth $25,000 after purchasing an additional 2,500 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Cytek Biosciences by 86.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,144 shares of the company's stock valued at $26,000 after purchasing an additional 2,388 shares in the last quarter. Federated Hermes Inc. increased its stake in Cytek Biosciences by 150.9% during the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after buying an additional 4,343 shares during the period. M&T Bank Corp purchased a new stake in Cytek Biosciences during the 4th quarter worth $52,000. Finally, Pallas Capital Advisors LLC acquired a new position in Cytek Biosciences in the 2nd quarter worth $50,000. Institutional investors and hedge funds own 69.46% of the company's stock.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source